Lv2
120 积分 2024-07-17 加入
Optimizing In Vivo CAR T-cell Engineering for Cancer Immunotherapy
12天前
已完结
In vivo CAR T cell engineering: design principles and open questions
12天前
已完结
Engineered cells as programmable mRNA delivery vehicles
16天前
已完结
Single-day nonactivated IL-18-armed CAR T cells establish a durable, stemlike state with enhanced persistence
17天前
已完结
Nexiguran Ziclumeran Gene Editing in Hereditary ATTR with Polyneuropathy
26天前
已完结
B cell depletion in autoimmune disease: in vivo CAR-T or T cell engagers?
29天前
已完结
Sialylated CD43 forms a glyco-immune barrier that restrains antileukemic immunity
1个月前
已完结
Base Editing of HBG1 and HBG2 Promoters for Sickle Cell Disease
1个月前
已完结
A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy
1个月前
已完结
Hypoxia-responsive CEA-targeted CAR T cells in CEA-positive solid tumors through intraperitoneal or intravenous infusion: a phase 1 trial
1个月前
已完结
皖公网安备34019202002308
